{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T18:10:49Z","timestamp":1782151849284,"version":"3.54.5"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jaut.2020.102549","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T01:19:25Z","timestamp":1602551965000},"page":"102549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Fingolimod reduces salivary infiltrates and increases salivary secretion in a murine Sj\u00f6gren's model"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9970-4627","authenticated-orcid":false,"given":"Philip L.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"McCulloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2020.102549_bib1","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/archinte.164.12.1275","article-title":"Clinical manifestations and early diagnosis of Sjogren's syndrome","volume":"164","author":"Kassan","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jaut.2020.102549_bib2","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: a meta-analysis","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jaut.2020.102549_bib3","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/art.23073","volume":"56","author":"Manoussakis","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102549_bib4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4049\/jimmunol.130.1.203","article-title":"Immunohistologic analysis of lymphoid infiltrates in primary Sj\u00f6gren's syndrome using monoclonal antibodies","volume":"130","author":"Adamson","year":"1983","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2020.102549_bib5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.semarthrit.2012.07.003","article-title":"The role of ectopic germinal centers in the immunopathology of primary Sj\u00f6gren\u2019s syndrome: a systematic review","volume":"42","author":"Risselada","year":"2013","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102549_bib6","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1002\/art.11311","article-title":"Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with sjogren's syndrome","volume":"48","author":"Salomonsson","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"9 Pt 2","key":"10.1016\/j.jaut.2020.102549_bib7","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/j.lpm.2012.05.025","article-title":"Predictors for the development of non-Hodgkin lymphoma in primary Sj\u00f6gren's syndrome","volume":"41","author":"Jonsson","year":"2012","journal-title":"Presse Med."},{"key":"10.1016\/j.jaut.2020.102549_bib8","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/ard.2010.144782","article-title":"Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sj\u00f6gren's syndrome","volume":"70","author":"Theander","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102549_bib9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2012.53","article-title":"Topical and systemic medications for the treatment of primary sjogren's syndrome","volume":"8","author":"Ramos-Casals","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"issue":"11","key":"10.1016\/j.jaut.2020.102549_bib10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (fingolimod): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jaut.2020.102549_bib11","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator fingolimod targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jaut.2020.102549_bib12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1124\/jpet.102.045658","article-title":"Amelioration of experimental autoimmune encephalomyelitis in lewis rats by fingolimod treatment","volume":"305","author":"Fujino","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.jaut.2020.102549_bib13","first-page":"439","article-title":"fingolimod, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration","volume":"2","author":"Kataoka","year":"2005","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jaut.2020.102549_bib14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2004.04.015","article-title":"Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice","volume":"153","author":"Webb","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jaut.2020.102549_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2249.2006.03175.x","article-title":"Inhibition of donor-derived T cells trafficking into target organs by fingolimod during acute graft-versus-host disease in small bowel transplantation","volume":"146","author":"Song","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2020.102549_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.TP.0000151005.37985.DE","article-title":"Fingolimod in corneal concordant xenotransplantation","volume":"79","author":"Sedlakova","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.jaut.2020.102549_bib17","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.transproceed.2004.03.052","article-title":"Fingolimod treatment prolongs skin graft survival in a completely incompatible strain combination","volume":"36","author":"Lima","year":"2004","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.jaut.2020.102549_bib18","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1161\/01.CIR.100.12.1322","article-title":"fingolimod, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation","volume":"100","author":"Hwang","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jaut.2020.102549_bib19","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0041-1345(98)01974-5","article-title":"fingolimod, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-cell infiltration into grafts","volume":"31","author":"Yanagawa","year":"1999","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.jaut.2020.102549_bib20","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0041-1345(98)01944-7","article-title":"Immunosuppressive action of fingolimod for renal allograft a rat model","volume":"31","author":"Kunikata","year":"1999","journal-title":"Transplant. Proc."},{"issue":"Suppl 17","key":"10.1016\/j.jaut.2020.102549_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1399-0012.2006.00596.x","article-title":"Fingolimod (fingolimod) in renal transplantation","volume":"20","author":"Budde","year":"2006","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.jaut.2020.102549_bib22","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/00007890-200109150-00002","article-title":"fingolimod: altered lymphocyte traffic results in allograft protection","volume":"72","author":"Brinkmann","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.jaut.2020.102549_bib23","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.4049\/jimmunol.160.10.5037","volume":"160","author":"Chiba","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2020.102549_bib24","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1167\/iovs.09-4769","article-title":"Evaluation of experimental autoimmune uveitis in mice treated with fingolimod","volume":"51","author":"Commodaro","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jaut.2020.102549_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/exer.1999.0777","article-title":"Effects of fingolimod, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats","volume":"70","author":"Kurose","year":"2000","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jaut.2020.102549_bib26","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ajpath.2011.10.008","article-title":"Therapeutic dosing of fingolimod (fingolimod) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier","volume":"180","author":"Copland","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jaut.2020.102549_bib27","first-page":"1896","article-title":"Alleles from chromosomes 1 and 3 of NOD mice combine to influence Sj\u00f6gren's syndrome-like autoimmune exocrinopathy","volume":"27","author":"Brayer","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2020.102549_bib28","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.10258","article-title":"Two NOD idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sj\u00f6gren's syndrome) on a healthy murine background","volume":"46","author":"Cha","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102549_bib29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.1070238","article-title":"Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists","volume":"296","author":"Mandala","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jaut.2020.102549_bib30","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.4049\/jimmunol.164.11.5761","article-title":"Fingolimod immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory","volume":"164","author":"Pinschewer","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2020.102549_bib31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00007890-199601270-00006","article-title":"A novel immunosuppressant, fingolimod, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation","volume":"61","author":"Suzuki","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.jaut.2020.102549_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-2249.1997.d01-885.x","article-title":"The in vivo induction of lymphocyte apoptosis in MRL-lpr\/lpr mice treated with fingolimod","volume":"107","author":"Suzuki","year":"1997","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2020.102549_bib33","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren\u2019s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren\u2019s Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102549_bib34","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren\u2019s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.jaut.2020.102549_bib35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1601-0825.2012.01932.x","article-title":"Biologics in oral medicine: sj\u00f6gren syndrome","volume":"19","author":"O\u2019Neill","year":"2013","journal-title":"Oral Dis."},{"issue":"9 Pt 2","key":"10.1016\/j.jaut.2020.102549_bib36","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/j.lpm.2012.05.024","article-title":"Biologic treatments in Sj\u00f6gren's syndrome","volume":"41","author":"Bowman","year":"2012","journal-title":"Presse Med."},{"key":"10.1016\/j.jaut.2020.102549_bib37","doi-asserted-by":"crossref","unstructured":"Nordmark G, Alm GV, R\u00f6nnblom L. Mechanisms of Disease: primary Sj\u00f6gren's syndrome and the type I interferon system. Nat. Rev. Rheumatol. 2, 262-269.","DOI":"10.1038\/ncprheum0173"},{"key":"10.1016\/j.jaut.2020.102549_bib38","first-page":"151","article-title":"Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sj\u00f6gren's syndrome","volume":"39","author":"Bacman","year":"1998","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jaut.2020.102549_bib39","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1046\/j.1365-2249.1996.42748.x","article-title":"Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sj\u00f6gren's syndrome","volume":"104","author":"Bacman","year":"1996","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2020.102549_bib40","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1073\/pnas.95.13.7538","article-title":"Transfer of human serum IgG to nonobese diabetic Ig mu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in sjogren's syndrome","volume":"95","author":"Robinson","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2020.102549_bib41","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/art.20998","article-title":"Activation of the type I interferon system in primary Sj\u00f6gren's syndrome: a possible etiopathogenic mechanism","volume":"52","author":"Bave","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102549_bib42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-3083.2012.02749.x","article-title":"Transcriptome analysis of the interferon-signature defining the autoimmune process of Sj\u00f6gren's syndrome","volume":"76","author":"Peck","year":"2012","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.jaut.2020.102549_bib43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1124\/jpet.102.045658","article-title":"Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by fingolimod treatment","volume":"305","author":"Fujino","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.jaut.2020.102549_bib44","first-page":"439","article-title":"fingolimod, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration","volume":"2","author":"Kataoka","year":"2005","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jaut.2020.102549_bib45","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2004.04.015","article-title":"Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice","volume":"153","author":"Webb","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jaut.2020.102549_bib46","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1167\/iovs.09-4769","article-title":"Evaluation of experimental autoimmune uveitis in mice treated with fingolimod","volume":"51","author":"Commodaro","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.jaut.2020.102549_bib47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/exer.1999.0777","article-title":"Effects of fingolimod, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats","volume":"70","author":"Kurose","year":"2000","journal-title":"Exp. Eye Res."},{"issue":"2","key":"10.1016\/j.jaut.2020.102549_bib48","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ajpath.2011.10.008","article-title":"Therapeutic dosing of fingolimod (fingolimod) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier","volume":"180","author":"Copland","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jaut.2020.102549_bib49","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0041-1345(98)01974-5","article-title":"fingolimod, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-cell infiltration into grafts","volume":"31","author":"Yanagawa","year":"1999","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.jaut.2020.102549_bib50","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0041-1345(98)01944-7","article-title":"Immunosuppressive action of fingolimod for renal allograft in a rat model","volume":"31","author":"Kunikata","year":"1999","journal-title":"Transplant. Proc."},{"issue":"Suppl 17","key":"10.1016\/j.jaut.2020.102549_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1399-0012.2006.00596.x","article-title":"Fingolimod in renal transplantation","volume":"20","author":"Budde","year":"2006","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.jaut.2020.102549_bib52","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/00007890-200109150-00002","article-title":"Fingolimod: altered lymphocyte traffic results in allograft protection","volume":"72","author":"Brinkmann","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.jaut.2020.102549_bib53","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.4049\/jimmunol.160.10.5037","volume":"160","author":"Chiba","year":"1998","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.jaut.2020.102549_bib54","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.24903","article-title":"Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sj\u00f6gren's syndrome","volume":"60","author":"Pijpe","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jaut.2020.102549_bib55","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jaut.2012.05.019","article-title":"The T cell in Sj\u00f6gren's syndrome: force majeure, not spectateur","volume":"39","author":"Singh","year":"2012","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2020.102549_bib56","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10875-012-9663-6","article-title":"B-cell tolerance defects in the B6.Aec1\/2 mouse model of Sjogren's syndrome","volume":"22","author":"Meng","year":"2012","journal-title":"J. Clin. Immunol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089684112030175X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089684112030175X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:26:20Z","timestamp":1760257580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089684112030175X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":56,"alternative-id":["S089684112030175X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2020.102549","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fingolimod reduces salivary infiltrates and increases salivary secretion in a murine Sj\u00f6gren's model","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2020.102549","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102549"}}